103 related articles for article (PubMed ID: 27989619)
1. Determinants of Treatment Eligibility in Veterans With Hepatitis C Viral Infection.
Taylor J; Carr-Lopez S; Robinson A; Malmstrom R; Duncan K; Maniar A; Re ACD; Carmichael JM
Clin Ther; 2017 Jan; 39(1):130-137. PubMed ID: 27989619
[TBL] [Abstract][Full Text] [Related]
2. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders.
Chainuvati S; Khalid SK; Kancir S; Shea M; Edwards J; Sernyak M; Wongcharatrawee S; Garcia-Tsao G
J Viral Hepat; 2006 Apr; 13(4):235-41. PubMed ID: 16611189
[TBL] [Abstract][Full Text] [Related]
3. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.
Lin M; Kramer J; White D; Cao Y; Tavakoli-Tabasi S; Madu S; Smith D; Asch SM; El-Serag HB; Kanwal F
Aliment Pharmacol Ther; 2017 Nov; 46(10):992-1000. PubMed ID: 28949020
[TBL] [Abstract][Full Text] [Related]
4. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection.
Bini EJ; Bräu N; Currie S; Shen H; Anand BS; Hu KQ; Jeffers L; Ho SB; Johnson D; Schmidt WN; King P; Cheung R; Morgan TR; Awad J; Pedrosa M; Chang KM; Aytaman A; Simon F; Hagedorn C; Moseley R; Ahmad J; Mendenhall C; Waters B; Strader D; Sasaki AW; Rossi S; Wright TL
Am J Gastroenterol; 2005 Aug; 100(8):1772-9. PubMed ID: 16086714
[TBL] [Abstract][Full Text] [Related]
5. Reasons for HCV non-treatment in underserved African Americans: implications for treatment with new therapeutics.
Schaeffer S; Khalili M
Ann Hepatol; 2015; 14(2):234-42. PubMed ID: 25671833
[TBL] [Abstract][Full Text] [Related]
6. Rate and predictors of treatment prescription for hepatitis C.
Butt AA; Justice AC; Skanderson M; Rigsby MO; Good CB; Kwoh CK
Gut; 2007 Mar; 56(3):385-9. PubMed ID: 17005764
[TBL] [Abstract][Full Text] [Related]
7. Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans.
Dollarhide AW; Loh C; Leckband SG; Endow-Eyer R; Robinson S; Meyer JM
J Clin Gastroenterol; 2007 Mar; 41(3):322-8. PubMed ID: 17426475
[TBL] [Abstract][Full Text] [Related]
8. Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.
Nordstrom EM; Keniston A; Baouchi F; Martinez-Camacho A
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):10-16. PubMed ID: 27755117
[TBL] [Abstract][Full Text] [Related]
9. Who needs direct-acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV-coinfected individuals.
Klein MB; Rollet KC; Hull M; Cooper C; Walmsley S; Conway B; Pick N;
Antivir Ther; 2013; 18(5):717-21. PubMed ID: 23211632
[TBL] [Abstract][Full Text] [Related]
10. Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus: The Veteran Birth Cohort.
Njei B; Esserman D; Krishnan S; Ohl M; Tate JP; Hauser RG; Taddei T; Lim J; Justice AC
Med Care; 2019 Apr; 57(4):279-285. PubMed ID: 30807449
[TBL] [Abstract][Full Text] [Related]
11. Curing Hepatitis C Virus Infection: Best Practices From the U.S. Department of Veterans Affairs.
Belperio PS; Chartier M; Ross DB; Alaigh P; Shulkin D
Ann Intern Med; 2017 Oct; 167(7):499-504. PubMed ID: 28973196
[TBL] [Abstract][Full Text] [Related]
12. Limited success of HCV antiviral therapy in United States veterans.
Cawthorne CH; Rudat KR; Burton MS; Brown KE; Luxon BA; Janney CG; Fimmel CJ
Am J Gastroenterol; 2002 Jan; 97(1):149-55. PubMed ID: 11808940
[TBL] [Abstract][Full Text] [Related]
13. Utility of a depression score to predict candidacy for hepatitis C virus therapy in veterans: a prospective longitudinal study.
Tavakoli-Tabasi S; Rowan P; Abdul-Latif M; Kunik ME; El-Serag HB
Aliment Pharmacol Ther; 2005 Feb; 21(3):235-42. PubMed ID: 15691297
[TBL] [Abstract][Full Text] [Related]
14. Spectrum of disease in U.S. veteran patients with hepatitis C.
Nguyen HA; Miller AI; Dieperink E; Willenbring ML; Tetrick LL; Durfee JM; Ewing SL; Ho SB
Am J Gastroenterol; 2002 Jul; 97(7):1813-20. PubMed ID: 12135041
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of Hepatitis C Virus Infection in the Veteran Population Undergoing Total Joint Arthroplasty: An Update.
Shapiro CBH; Cheung RC; Giori NJ
J Arthroplasty; 2021 Feb; 36(2):467-470. PubMed ID: 32900563
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment assessment and predictors of hepatitis C virus treatment in US veterans coinfected with HIV and hepatitis C virus.
Backus LI; Boothroyd DB; Phillips BR; Mole LA
J Viral Hepat; 2006 Dec; 13(12):799-810. PubMed ID: 17109679
[TBL] [Abstract][Full Text] [Related]
17. Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders.
Huckans MS; Loftis JM; Blackwell AD; Linke A; Hauser P
Subst Abuse Treat Prev Policy; 2007 Jan; 2():4. PubMed ID: 17222348
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals.
Belperio PS; Shahoumian TA; Mole LA; Backus LI
Hepatology; 2017 Jul; 66(1):27-36. PubMed ID: 28240789
[TBL] [Abstract][Full Text] [Related]
19. Disease characteristics and treatment patterns in veterans with rheumatoid arthritis and concomitant hepatitis C infection.
Patel R; Mikuls TR; Richards JS; Kerr G; Cannon GW; Baker JF
Arthritis Care Res (Hoboken); 2015 Apr; 67(4):467-74. PubMed ID: 25187185
[TBL] [Abstract][Full Text] [Related]
20. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life.
Cacoub P; Rosenthal E; Halfon P; Sene D; Perronne C; Pol S
J Viral Hepat; 2006 Oct; 13(10):678-82. PubMed ID: 16970599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
